glp 1 agonist action Frontiers Frontiers | GLP-1 Receptor Agonists

After discontinuing its internal GLP-1 in May of 2025 for causing liver issues, Pfizer won a bidding war against seven other companies for Metsera, which is developing a variety of incretin assets, paying $10 billion in one of 2025s largest M&A deals

Mansi C, Savarino V, Vigneri S, et al

Flavonoids against the Warburg phenotypeconcepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism

doi: 10.1186/s12958-021-00823-z 60 LiXHeYYanQKuaiDZhangHWangYet al

Short-acting GLP-1RAs generally lower postprandial blood glucose by delaying gastric emptying time, while long-acting GLP-1RAs reduce fasting glucagon or increase fasting insulin concentration [37]